Skip to main content
MNKD
NASDAQ Life Sciences

MannKind Q2 Revenue Jumps 43% to $109M, Narrows Loss; Nintedanib DPI Phase 2 Planned

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.12
Mkt Cap
$1.322B
52W Low
$2.23
52W High
$6.51
52W Position info
85% above low
Off High info
37% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

MNKD sits 85% above its 52-week low of $2.23.

Summary

MannKind delivered a strong Q2 with revenue surging 43% year-over-year to $109.4 million, driven by Furoscix and collaboration income, while the GAAP net loss narrowed to $19 million. The Phase 1b INFLO-1 trial of inhaled nintedanib DPI met its safety goal in IPF patients, clearing the way for a global Phase 2 study. Additionally, the ralinepag DPI IND filing remains on track for year-end, with United Therapeutics paying a $5 million milestone. This follows a series of positive regulatory and clinical developments, including FDA approvals for Afrezza pediatric use and Furoscix ReadyFlow, and a recent $50 million private placement. The pipeline progress and revenue growth reinforce the company's turnaround narrative, with analyst consensus strongly bullish at a mean $7.50 target.

At the time of this announcement, MNKD was trading at $4.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.23 to $6.51. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

MNKD - Latest Insights

MNKD
Nov 05, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.79
Real-time Price: $3.88 info
Change: +$0.085 (+2%) info
Market Cap: $1.24B info
MNKD
Nov 05, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.76
Real-time Price: $3.88 info
Change: +$0.115 (+3%) info
Market Cap: $1.24B info
MNKD
Sep 09, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.28
Real-time Price: $3.88 info
Change: -$0.405 (-9%) info
Market Cap: $1.24B info
MNKD
Jul 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.03
Real-time Price: $3.88 info
Change: -$0.155 (-4%) info
Market Cap: $1.24B info
MNKD
Jul 24, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.11
Real-time Price: $3.88 info
Change: -$0.235 (-6%) info
Market Cap: $1.24B info